Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients

Completed · Phase 4

Conditions studied: Febrile Neutropenia

In brief

Primary: To determine the serum pharmacokinetics (PK) of doripenem in febrile neutropenic patients. Secondary: Monte Carlo Simulations Tested Against Various Gram-negative Isolates and Reported as Probability of Target Attainment (40% Time (fT)\> minimum inhibitory concentration (MIC))

Key facts

Study ID

NCT01401010

Run by

Gary E. Stein, Pharm.D.

People needed

12

Starts

2010-08-01

Expected to finish

2012-02-01

Last updated by the study team

2015-10-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adult neutropenic (< 500 cells) patients who are febrile

You may not qualify if…

• Patients with Creatinine Clearance < 30 ml/min or allergy to carbapenems will be excluded.

Where it is running

• Sparrow Hospital — Lansing, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.